
News from Los Angeles Downtown News - The Voice of Downtown Los Angeles…
Top Los Angeles Downtown News - The Voice of Downtown Los Angeles… News

Amgen · Thousand OaksAmgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on Tuesday. The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previ…See the Story
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis - Amgen (NASDAQ:AMGN)
84% Center coverage: 13 sources